Keros

BYOMass

This company develops biologic and small molecule drugs targeting the TGF-beta superfamily to treat metabolic, fibrotic and age-related diseases for patients with unmet needs.

Origo Biopharma

This clinical-stage biotechnology company develops small molecule therapies targeting the transforming growth factor beta pathway to treat fibrosis and cancer in healthcare patients.

Promedior

This biotechnology company develops drug therapies to treat rare fibrotic diseases for patients with conditions such as idiopathic pulmonary fibrosis and myelofibrosis.

ProteoValent Therapeutics

This company develops targeted protein degrader therapies for cancer and haematology patients.

Kither Biotech

This company develops inhaled therapies for patients with respiratory diseases such as chronic obstructive pulmonary disease and cystic fibrosis.

Akero Therapeutics

This company develops metabolic disease treatments for patients with metabolic dysfunction-associated steatohepatitis and other liver conditions.

Biotheryx

The company develops protein degrader medicines for patients with cancer and inflammatory diseases.

Thrasos

This biotherapeutics company develops targeted peptide therapies for the prevention and treatment of kidney diseases for patients with acute and chronic renal conditions.